Komori
K Pharma (4896) · PolicyRestated

No-Dividend and Retained Earnings Policy Prioritizing Research and Development

First written in FY2023. 6 of 7 entries say "Restated". Latest entry: FY2026-H1.

7entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY2026-H12024: 320242025: 220252026: 22026
Same theme, other companies
No-Dividend Policy Prioritizing R&D FundingA theme 36 companies write about · 8 as a headwind · 19 as a tailwind

The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.

31 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 36 companies compared. The sentences above are computed from all 36.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「No per-share dividend is presented because no dividends were paid.」

    No dividend was paid during the interim accounting period.
  2. FY2025RestatedAnnual report

    「We have paid no dividends since our incorporation, including for the current fiscal year. We intend to use retained earnings for research and development funding required for future business expansion.」

    The company maintains its policy of paying no dividends and using retained earnings for research and development.
  3. FY2025-H1RestatedAnnual report

    「No per-share dividend is presented because no dividends were paid.」

    The company did not pay a dividend in the current interim accounting period.
  4. FY2024RestatedAnnual report

    「We have paid no dividends since our incorporation, including for the current fiscal year. We intend to use retained earnings for research and development funding required for future business expansion.」

    The company continues its policy of paying no dividends and prioritizing retained earnings for research and development.
  5. FY2024-H1RestatedAnnual report

    「No per-share dividend is presented because no dividends were paid.」

    The company did not pay a dividend in the current interim accounting period.
  6. FY2024-Q1RestatedAnnual report

    「No per-share dividend is presented because no dividends were paid.」

    The company did not pay a dividend in the first quarter.
  7. FY2023First statedAnnual report

    「Although we recognize maximizing shareholder returns as one of our important management objectives, we believe it is important to build retained earnings to strengthen our financial base over the long term and achieve continuous business expansion. Accordingly, we have paid no dividends since our incorporation, including for the current fiscal year.」

    The company intends for the time being to pay no dividends and to direct retained earnings toward research and development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
No-Dividend and Retained Earnings Policy Prioritizing Research and Development | K Pharma,Inc. (4896) | Komori